Lyra Therapeutics Shares Are Trading Lower on Continued Weakness After the Company on Monday Announced the ENLIGHTEN 1 Trial Did Not Meet Its Primary Endpoint. Also, Jefferies Downgraded the Stock From Buy to Hold and Lowered Its Price Target From $10...
Lyra Therapeutics Shares Are Trading Lower on Continued Weakness After the Company on Monday Announced the ENLIGHTEN 1 Trial Did Not Meet Its Primary Endpoint. Also, Jefferies Downgraded the Stock From Buy to Hold and Lowered Its Price Target From $10...
Lyra Therapeutics周一宣布ENLIGHTEN 1试验未达到其主要终点后，该公司股价因持续疲软而走低。此外，杰富瑞将股票评级从买入下调至持有，并将其目标股价从10美元下调...
Lyra Therapeutics Shares Are Trading Lower on Continued Weakness After the Company on Monday Announced the ENLIGHTEN 1 Trial Did Not Meet Its Primary Endpoint. Also, Jefferies Downgraded the Stock From Buy to Hold and Lowered Its Price Target From $10 to $0.5.
Lyra Therapeutics周一宣布ENLIGHTEN 1试验未达到其主要终点后，该公司股价因持续疲软而走低。此外，杰富瑞将该股的评级从买入下调至持有，并将其目标股价从10美元下调至0.5美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。